Hair Relaxer Cancer Lawsuit: What’s Been Proven So Far

Last updated: July 2026

The hair relaxer cancer lawsuit is a federal mass tort claiming chemical relaxers caused uterine, endometrial, and ovarian cancers. As of July 2026, nearly 12,000 cases are pending in MDL 3060 in Chicago. No trial has happened and nothing has settled, but key science rulings arrive before the first trials, expected in 2027.

If you or a family member used chemical relaxers for years and later received a cancer diagnosis, this page explains what has actually been established so far: in published studies, in court filings, and in the rulings issued to date. The short version is that the science is serious, the litigation is enormous, and the biggest tests are still ahead.

What Is the Hair Relaxer Cancer Lawsuit About?

Thousands of women, most of them Black women who began using relaxers at a young age, allege that manufacturers sold products containing endocrine-disrupting chemicals, including phthalates such as DEHP and parabens, without warning anyone about cancer risks. Some straightening products also release formaldehyde, a known carcinogen.

The defendants include L’Oréal USA, SoftSheen-Carson, Strength of Nature, Namaste Laboratories, Avlon, and other companies behind brands like Dark and Lovely, Just for Me, Optimum, and Motions. Revlon is named as well, though its bankruptcy limits what plaintiffs can recover from it.

The federal cases are consolidated in multidistrict litigation, MDL 3060, before Judge Mary M. Rowland in the Northern District of Illinois. As of July 1, 2026, the MDL held 11,877 pending cases, one of the largest active mass torts in the country. More cases are moving through state courts, including in Cook County, Illinois.

What Does the Science Actually Show?

The litigation was triggered by a 2022 study from the National Institutes of Health’s Sister Study, published in the Journal of the National Cancer Institute. It followed roughly 33,900 women for about 11 years. Women who used chemical straightening products more than four times per year developed uterine cancer at about 2.5 times the rate of women who never used them.

The absolute numbers matter for context. The study estimated that by age 70, about 1.64% of never users would develop uterine cancer, compared with 4.05% of frequent users. That is still a minority of users, but it is a meaningful jump for such a widely used product.

These are association studies. They show a consistent statistical link, and researchers have a plausible biological explanation: relaxers can contain hormone-disrupting chemicals, scalp burns and lesions are common during application, and uterine cancer is hormone sensitive. What the studies cannot do on their own is prove that a specific product caused a specific woman’s cancer. That fight happens in court.

What Has Happened in Court So Far?

The first cases were filed within days of the 2022 study. Here is the condensed timeline.

Two rulings stand out. In November 2023, Judge Rowland refused to throw out the core failure to warn and design defect claims, rejecting most of the manufacturers’ early arguments. In February 2025, she kept additional defendants, including Wella and John Paul Mitchell Systems, in the case.

Then in April 2026, after expressing frustration with the slow party-driven selection process, the judge took direct control of choosing the bellwether cases: the small group of representative lawsuits that will be tried first. Preparing those cases for trial is now the center of the litigation.

Has Anything Been Proven in Court Yet?

No. That is the honest answer, and it matters for anyone weighing a claim.

No jury has heard a hair relaxer case. No court has ruled that relaxers cause cancer. There is no settlement fund. What has been established is narrower but still significant: the claims are legally viable, the defendants could not get the cases dismissed early, and peer-reviewed federal research supports the alleged link strongly enough to sustain a massive consolidated litigation.

The next hurdle is the biggest one. Under the Daubert standard, Judge Rowland must decide whether the plaintiffs’ experts can testify that relaxers are capable of causing uterine and ovarian cancer. Briefing on these expert challenges and on summary judgment runs through late 2026. If the experts survive, trials follow and settlement pressure rises sharply. If they are excluded, much of the litigation could collapse.

Who Can Still File a Hair Relaxer Cancer Lawsuit?

Every law firm sets its own criteria, but most accepted cases share a few core facts. Typical qualifying plaintiffs:

• Used chemical hair relaxers or straighteners regularly, often defined as several times a year for multiple years
• Were later diagnosed with uterine cancer, endometrial cancer, or ovarian cancer
• Can file within their state’s statute of limitations, commonly one to three years from diagnosis or from discovery of the link

Uterine and endometrial cancer cases are considered the strongest because the published research is deepest there. Some firms also accept ovarian cancer cases. Breast cancer and fibroid claims are far less common in the MDL. Medical records and proof of product use (receipts, salon records, photos, witness statements) make any case stronger.

What Settlement Amounts Are Being Discussed?

No settlement exists, so every number you see online is a projection. Attorneys following the litigation have floated ranges from roughly $100,000 to more than $1 million for the strongest uterine cancer cases, with lower values for weaker claims. Treat those figures as educated guesses, not promises.

Real values will depend on the expert rulings, the first bellwether verdicts, each defendant’s finances (Revlon’s bankruptcy is a genuine constraint), and individual facts such as age at diagnosis, treatment received, and usage history. The court has also put machinery in place for settlement talks to run alongside the trial track.

What Happens Next?

The rest of 2026 belongs to the experts. Case-specific expert reports, Daubert motions, and summary judgment briefing are due in late 2026, with rulings and final trial preparation expected in early 2027. The first bellwether trial is broadly expected in 2027.

Watch three signals: the Daubert rulings, the outcome of the first trial, and any early individual settlements. In past mass torts, one or two plaintiff verdicts have changed the settlement math for every pending case.

The Bottom Line

So what has the hair relaxer cancer lawsuit actually proven so far? In court, nothing final: no verdicts, no settlements, no causation ruling. But the claims have survived every early legal attack, the case count is near 12,000 and still growing, and respected federal research links frequent relaxer use to roughly double the uterine cancer risk. For injured women, the practical takeaway is simple. Filing deadlines are set by state law and keep running, so having a case evaluated now costs nothing and protects your options.

This article is general information, not legal or medical advice. Litigation facts change quickly. Talk to a licensed attorney in your state about your specific situation.

Hair Relaxer Lawsuit FAQ

Is there a hair relaxer lawsuit settlement yet?

No. As of July 2026 there are no global settlements and no jury verdicts in the federal hair relaxer litigation. Nearly 12,000 cases are pending in MDL 3060. Most legal observers expect serious settlement talks only after the court rules on expert testimony and the first bellwether trials produce verdicts, likely in 2027.

How much could a hair relaxer settlement be worth?

Nobody knows yet. Attorney projections have ranged from roughly $100,000 to more than $1 million for strong uterine cancer cases, but these are educated guesses, not offers. Real values will depend on expert rulings, bellwether verdicts, each plaintiff’s diagnosis, her usage history, and the strength of her medical records.

Which cancers qualify for a hair relaxer claim?

Uterine cancer and endometrial cancer are the strongest claims because they are backed by the most published research. Ovarian cancer claims are also being filed. Breast cancer and uterine fibroid claims exist but are generally weaker, and many firms are not accepting them. A documented history of regular relaxer use is also required.

When will the first hair relaxer trial happen?

The court selected bellwether trial cases in April 2026, and expert and summary judgment briefing runs through late 2026 and into early 2027. Most observers expect the first trial in 2027. That first verdict will not bind other plaintiffs, but it will heavily influence settlement negotiations for everyone else.

Is it too late to file a hair relaxer cancer lawsuit?

Not necessarily. New cases were still being filed in mid-2026. Deadlines depend on your state’s statute of limitations, which often runs one to three years from diagnosis or from when you connected the cancer to relaxer use. Because these deadlines vary and expire, speak with a lawyer promptly.